Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

1. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery

A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features (...) in email: Save Cancel Create a file for external citation management software Create file Cancel Actions Cite Share Permalink Copy Page navigation World J Surg Actions . 2020 Mar 19. doi: 10.1007/s00268-020-05458-6. Online ahead of print. A Double-Blind, Randomized Controlled Trial of Pre-incision Wound Infiltration Using Diclofenac Versus Bupivacaine for Post-operative Pain Relief in Open Thyroid and Parathyroid Surgery , , , Affiliations Expand Affiliations 1 Department of Surgery, University

2020 EvidenceUpdates

2. Diclofenac: a habit that needs changing

Diclofenac: a habit that needs changing Prescrire IN ENGLISH - Spotlight ''Diclofenac: a habit that needs changing'', 1 December 2019 {1} {1} {1} | | > > > Diclofenac: a habit that needs changing Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Diclofenac: a habit that needs changing Diclofenac, a nonsteroidal anti-inflammatory drug (NSAID (...) ), is routinely used, despite evidence of a greater risk of adverse cardiovascular events when compared with other NSAIDs such as ibuprofen or naproxen, whereas it offers no additional benefit. Exposure to a nonsteroidal anti-inflammatory drug (NSAID) increases the risk of adverse cardiovascular events. For many years, diclofenac has been considered a good choice of NSAID, and using it has become a habit. The results of an extensive Danish study confirm the data already available: as compared with ibuprofen

2019 Prescrire

3. Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial (Abstract)

Pentazocine, a Kappa-Opioid Agonist, Is Better Than Diclofenac for Analgesia in Acute Pancreatitis: A Randomized Controlled Trial The ideal analgesic is not known for patients with acute pancreatitis (AP). Concerns have been raised about serious adverse effects of opioid analgesics increasing the severity of AP. We hypothesized that nonsteroidal anti-inflammatory drugs might be better analgesics because of their anti-inflammatory effect. Our objective was to compare pentazocine, an opioid (...) , and diclofenac, a nonsteroidal anti-inflammatory drug, for adequate analgesia in patients with AP.In a double-blind randomized controlled trial, patients with AP were randomized to either intravenous diclofenac 75 mg or pentazocine 30 mg. Fentanyl was given as a rescue analgesic through a patient-controlled analgesia pump. Primary outcome was pain relief measured objectively by the dose of fentanyl required as the rescue analgesic, pain-free period, and numbers of effective and ineffective demands

2019 EvidenceUpdates

4. Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography (Abstract)

Combination of Diclofenac and Sublingual Nitrates Is Superior to Diclofenac Alone in Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography Acute pancreatitis is a major adverse event of endoscopic retrograde cholangiopancreatography (ERCP). Rectal administration of nonsteroidal anti-inflammatory drugs (NSAIDs) decreases the incidence of post-ERCP pancreatitis (PEP). Little is known about the combined effects of sublingual nitrate and NSAIDs. We performed a randomized (...) trial to assess whether the combination of NSAIDs and sublingual nitrate is more effective than NSAIDs alone in preventing PEP.In a prospective superiority trial, eligible patients underwent ERCP at 12 endoscopic units in Japan, from March 2015 through May 2018. Patients were randomly assigned to groups given diclofenac suppositories (50 mg) within 15 minutes after the endoscopic procedure alone (diclofenac-alone group, n = 442) or in combination with sublingual isosorbide dinitrate (5 mg) 5 minutes

2019 EvidenceUpdates

5. Diclofenac use and cardiovascular risks: series of nationwide cohort studies. Full Text available with Trip Pro

Diclofenac use and cardiovascular risks: series of nationwide cohort studies. To examine the cardiovascular risks of diclofenac initiation compared with initiation of other traditional non-steroidal anti-inflammatory drugs, initiation of paracetamol, and no initiation.Series of 252 nationwide cohort studies, each mimicking the strict design criteria of a clinical trial (emulated trial design).Danish, nationwide, population based health registries (1996-2016).Individuals eligible for inclusion (...) were all adults without malignancy; schizophrenia; dementia; or cardiovascular, kidney, liver, or ulcer diseases (that is, with low baseline risk). The study included 1 370 832 diclofenac initiators, 3 878 454 ibuprofen initiators, 291 490 naproxen initiators, 764 781 healthcare seeking paracetamol initiators matched by propensity score, and 1 303 209 healthcare seeking non-initiators also matched by propensity score.Cox proportional hazards regression was used to compute the intention to treat

2018 BMJ

6. Diclofenac

Diclofenac Top results for diclofenac - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for diclofenac The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

7. Compounded Topical Diclofenac for the Treatment of Inflammation in Adults: Clinical Effectiveness, Cost-Effectiveness and Guidelines

Compounded Topical Diclofenac for the Treatment of Inflammation in Adults: Clinical Effectiveness, Cost-Effectiveness and Guidelines Compounded Topical Diclofenac for the Treatment of Inflammation in Adults: Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Compounded Topical Diclofenac for the Treatment of Inflammation in Adults: Clinical Effectiveness, Cost-Effectiveness and Guidelines Compounded Topical Diclofenac for the Treatment (...) of Inflammation in Adults: Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: November 8, 2017 Project Number: RB1159-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of prescription-strength compounded topical diclofenac for the treatment of adults with inflammation? What is the cost-effectiveness of prescription-strength compounded topical diclofenac for the treatment of adults with inflammation? What

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. (Abstract)

Comparison of Intravitreal Bevacizumab and Intravitreal Diclofenac in the Treatment of Diabetic Macular Edema: a 6-month Follow-up. The aim of this study was to compare the effect of intravitreal diclofenac, a non-steroidal anti-inflammatory drug (NSAID), with that of bevacizumab, a well-known anti-vascular endothelial growth factor (VEGF) drug, in the treatment of diabetic macular edema (DME). Diclofenac was chosen in this study because it has both features of NSAIDs and corticosteroids (...) by inhibiting the cyclooxygenase (COX) and lipoxygenase pathways, respectively. In this non-randomized comparative interventional case series, 64 eyes from 32 patients with bilateral naïve DME were selected and every eye was randomly assigned to intravitreal injection of bevacizumab (IVB) or diclofenac (IVD). After exclusion of some patients because of short follow-up duration or less than two intravitreal injections, finally, 52 eyes from 26 patients were analyzed. Of those, 26 eyes received 500 µg/0.1 mL

2017 Medical hypothesis, discovery & innovation ophthalmology journal Controlled trial quality: uncertain

9. Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen

Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen Prescrire IN ENGLISH - Spotlight ''Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen'', 1 January 2016 {1} {1} {1} | | > > > Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |  (...)  |   |   |   |   |   |   |  Spotlight Nonsteroidal anti-inflammatory drugs (NSAIDs): avoid cox-2 inhibitors, diclofenac and high-dose ibuprofen When pain medication is required, paracetamol (alias acetaminophen) is the reference drug. Among the nonsteroidal anti-inflammatories (NSAIDs), naproxen or ibuprofen (not exceeding 1200 mg a day) are the drugs that carry the least exposure to cardiac disorders. When pain medication is needed

2016 Prescrire

10. Does topical diclofenac relieve osteoarthritis pain?

Does topical diclofenac relieve osteoarthritis pain? Does topical diclofenac relieve osteoarthritis pain? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Does topical diclofenac relieve osteoarthritis pain? View/ Open Date 2015-02 Contributor Format Metadata Abstract Q: Does topical diclofenac relieve osteoarthritis (...) pain? Evidence-based answer: Yes, at least in the short term. Topical diclofenac, with and without dimethyl sulfoxide (DMSO), modestly improves pain and function scores (by 4%-8%) for as long as 12 weeks in patients with osteoarthritis (OA) of the knee (strength of recommendation [SOR]: A, meta-analyses of multiple randomized controlled trials [RCTs]). Topical diclofenac modestly decreases pain scores in patients with OA of the hand in the short term (by 9% at 6 weeks) but no more than placebo at 8

2015 Clinical Inquiries

11. Compounded Diclofenac Cream for Topical Anti-Inflammatory Treatment

Compounded Diclofenac Cream for Topical Anti-Inflammatory Treatment Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered (...) study only. It may not be copied, posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Compounded Diclofenac Cream for Topical Anti

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors

Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors Aceclofenac is now contraindicated in patients with certain established cardiovascular diseases. Published 22 January 2015 From (...) aceclofenac treatment after careful consideration of any significant risk factors for cardiovascular events, eg hypertension hyperlipidaemia diabetes mellitus smoking Aceclofenac (Preservex) is a non-steroidal anti-inflammatory drug (NSAID) licensed for the relief of pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Aceclofenac has little pharmacological activity itself; its main mode of action is through its metabolites which include diclofenac and 4’-hydroxy

2015 MHRA Drug Safety Update

13. Oral diclofenac no longer available without prescription

Oral diclofenac no longer available without prescription Oral diclofenac no longer available without prescription - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Oral diclofenac no longer available without prescription Oral diclofenac is associated with a small increased risk of cardiovascular side effects and is therefore no longer available over the counter. Published 22 January 2015 From: Therapeutic area: , When prescribing or dispensing diclofenac, consider that: oral (...) diclofenac must not be sold without prescription a for non-prescription diclofenac the in June 2013 topical formulations of diclofenac (eg gel and cream) remain available for sale over the counter Advice to give to patients: if you have recently bought diclofenac tablets without a prescription and continue to need pain relief, speak to your prescriber or pharmacist who can advise you on suitable alternatives - there is no problem if you wish to stop taking diclofenac in the meantime if you have been

2015 MHRA Drug Safety Update

14. Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc

Flector (diclofenac epolamine) - short-term symptomatic treatment of acute episodes of: extra-articular rheumatism such as scapulohumeral periarthritis, tendonitis, bursitis; microcrystalline arthritis; osteoarthritis etc HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 FLECTOR 50 mg, granules for oral solution in single-dose sachets (...) B/21 (CIP: 34009 352 642 9 9) Applicant: GENEVRIER INN diclofenac epolamine ATC code (2012) M01AB05 (Antiinflammatory and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based medicines at the Committee’s request, in compliance with Article R-163-21 of the French Social Security Code Lists concerned National Health Insurance (French Social Security Code L.162-17) Inclusion for hospital use (French Public

2014 Haute Autorite de sante

15. Voltarene (diclofenac sodium)

Voltarene (diclofenac sodium) HAS - Medical, Economic and Public Health Assessment Division 1/40 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 VOLTARENE 25 mg, gastro-resistant coated tablet B/30 (CIP: 34009 338 144 5 8) VOLTARENE 50 mg, gastro-resistant coated tablet B/30 (CIP: 34009 323 511 7 6) VOLTARENE LP 75 mg, prolonged-release coated tablet B/30 (CIP: 34009 335 920 4 2) VOLTARENE LP 100 mg (...) , prolonged-release coated tablet B/15 (CIP: 34009 324 604 9 6) VOLTARENE ENFANT, suppository B/10 (CIP: 34009 322 395 3 5) VOLTARENE 100 mg, suppository B/10 (CIP: 34009 322 143 4 1) VOLTARENE 75 mg/3 ml, solution for injection B/2 (CIP: 34009 324 522 2 4) Applicant: NOVARTIS PHARMA SAS INN diclofenac sodium ATC code (2012) M01AB05 (Antiinflammatory and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based

2014 Haute Autorite de sante

16. Voltarendolo (diclofenac potassium) - Symptomatic treatment of painful conditions of mild to moderate intensity and/or fever

Voltarendolo (diclofenac potassium) - Symptomatic treatment of painful conditions of mild to moderate intensity and/or fever HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 VOLTARENDOLO 12.5 mg, coated tablet B/30 tablets (CIP: 34009 359 411 2 1) Applicant: NOVARTIS SANTÉ FAMILIALE S.A.S. INN diclofenac potassium ATC Code (2012 (...) ): N02BG (Other analgesics and antipyretics) Reason for the review Re-assessment of the Actual Benefit of all medicines based on diclofenac administered systemically at the request of the Committee, pursuant to Article R-163-21 of the French Social Security Code Renewal of inclusion on the list of medicinal products refundable by National Health Insurance Lists concerned National Health Insurance (French Social Security Code L.162 17) Hospital use (French Public Health Code L.5123-2) Indication

2014 Haute Autorite de sante

17. Artotec (diclofenac sodium, misoprostol) - treatment of rheumatic diseases

Artotec (diclofenac sodium, misoprostol) - treatment of rheumatic diseases HAS - Medical, Economic and Public Health Assessment Division 1/39 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 5 February 2014 ARTOTEC 50 mg/0.2 mg, tablet B/30 (CIP: 34009 336 492 6 5) ARTOTEC 75 mg/0.2 mg, tablet B/20 (CIP: 34009 352 654 7 0) Applicant: PFIZER INN diclofenac sodium, misoprostol ATC code (2012) M01AB55 (Antiinflammatory (...) and antirheumatic products, non-steroids) Reason for the review Re-assessment of the Actual Benefit of all systemically administered diclofenac-based medicines at the Committee’s request, in compliance with Article R-163-21 of the French Social Security Code Lists concerned National Health Insurance (French Social Security Code L.162-17) Inclusion for hospital use (French Public Health Code L.5123-2) Indications concerned ARTOTEC 50 mg/0.2 mg: “Symptomatic treatment of rheumatic diseases in at-risk patients

2014 Haute Autorite de sante

18. Diclofenac

Diclofenac USE OF DICLOFENAC IN PREGNANCY 0344 892 0909 USE OF DICLOFENAC IN PREGNANCY (Date of issue: July 2014 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) used (...) to treat acute and chronic pain (including dysmenorrhoea) and in the management of rheumatoid arthritis. Some studies have suggested that use of NSAIDs in early pregnancy may be associated with an increased risk of spontaneous abortion. Data regarding diclofenac use are insufficient to assess the risk for this specific NSAID. NSAID use in pregnancy has been associated with increased risks of various different congenital malformations, including cardiovascular defects and oral clefts. No association

2014 UK Teratology Information Service

19. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial (Abstract)

Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial Tanezumab, a monoclonal antibody, inhibits nerve growth factor and reduces chronic pain. This randomised, double-blind, controlled multicentre study was conducted to evaluate the efficacy and safety of tanezumab added to oral diclofenac sustained release (DSR) in patients (...) not confirm osteonecrosis in any patient.Addition of tanezumab to DSR resulted in significant improvements in pain, function and global assessments in patients with OA. Although no new safety signals were observed, the higher incidence of adverse events in the tanezumab+diclofenac group suggests that combination therapy is unfavourable. Further investigations of tanezumab monotherapy for OA pain treatment are required.NCT00864097.Published by the BMJ Publishing Group Limited. For permission to use (where

2013 EvidenceUpdates Controlled trial quality: predicted high

20. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Full Text available with Trip Pro

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Brereton N, Winn B, Akehurst (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI), compared with diclofenac plus a PPI, for patients with osteoarthritis. The authors

2013 NHS Economic Evaluation Database.